[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371672-105":59,"doc-detail-371672-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","liver-transplantation-for-unresectable-colorectal-liver-metastases","Liver Transplantation for Unresectable Colorectal Liver Metastases","","Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide, and nearly half of patients develop metastases, most commonly in the liver. Curative liver resection remains the standard for colorectal liver metastases (CRLM), yet many patients are initially unresectable and recurrence rates are high. Systemic chemotherapy is the main option, while immune checkpoint inhibitors, hepatic artery infusion, and locoregional therapies are explored. Liver transplantation (LT), once abandoned, is being reconsidered with improved surgical methods and immunosuppression, and this review summarizes evidence on selection, outcomes, and future directions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/liver-transplantation-for-unresectable-colorectal-liver-metastases/371672/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/liver-transplantation-for-unresectable-colorectal-liver-metastases/371672.png","ImageObject",300,407,{"name":92,"@type":93},"Terk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are many patients with colorectal liver metastases (CRLM) not eligible for surgery initially?","Question",{"text":112,"@type":113},"Up to about 80% of patients with CRLM are not candidates for surgical resection at initial presentation, and recurrence remains common after curative-intent hepatic resection.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the primary treatment approach for unresectable CRLM?",{"text":117,"@type":113},"Systemic chemotherapy is the cornerstone for unresectable CRLM, aiming to reduce progression, improve quality of life, and potentially downstage patients to resectability.",{"name":119,"@type":110,"acceptedAnswer":120},"What factors led to renewed interest in liver transplantation for unresectable CRLM?",{"text":121,"@type":113},"Advances in surgical technique, better immunosuppression, expansion of the donor pool, and growing experience with liver transplant for hepatocellular carcinoma and hilar cholangiocarcinoma have renewed interest in this oncologic strategy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371672,1790217584,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099525198933,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Liver Transplantation for Unresectable Colorectal Liver Metastases  \nYash Kadakia, MD 1 , Omar Bushara, MD 1, Maarouf Hoteit, MD2 and Peter Abt, MD 1   \nTechnology in Cancer Research & Treatment  \nVolume 24: 1-9 © The Author(s) 2025 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/15330338251361238](DOI: 10.1177/15330338251361238)[ ](DOI: 10.1177/15330338251361238)[journals.sagepub.com/home/tct](journals.sagepub.com/home/tct)  \nAbstract  \nColorectal cancer (CRC) is the third most common malignancy worldwide and a leading cause of cancer-related death. Nearly half of CRC patients develop metastatic disease, with the liver being the most frequent site of metastases. While curative-intent surgical resection remains the gold standard for colorectal liver metastases (CRLM), most patients are initially ineligible for surgery, and recurrence rates remain high. Systemic chemotherapy is the primary treatment for unresectable CRLM, with some patients achieving downstaging to surgical eligibility. Alternative approaches, including immune checkpoint inhibitors for MSIH/dMMR cancers, hepatic artery infusion pumps, and locoregional therapies, have been explored to improve survival. Liver transplantation (LT) was initially abandoned for CRLM due to poor outcomes, but advancements in surgical techniques, immunosuppression, and donor availability have reignited interest in this approach. With LT becoming an established option for hepatocellular carcinoma and cholangiocarcinoma, its potential role in treating unresectable CRLM is being reconsidered. This review provides the latest evidence on LT for CRLM, including patient selection, outcomes, and future research directions.  \nKeywords  \nliver cancer, colorectal cancer, transplant, adjuvant chemotherapy, metastasis  \nReceived: 27 March 2025; revised: 25 June 2025; accepted: 8 July 2025  \nIntroduction  \nColorectal cancer (CRC) is the third most common malignancy worldwide and second leading cause of cancer-related death in the United States. Nearly 50% of patients will ultimately develop metastatic disease, with the liver being the common site of metastases in approximately 70% of cases.1 For resectable colorectal liver metastasis (CRLM), the gold standard treatment is curative-intent surgical resection. In conjunction with modern systemic therapies, ﬁve-year overall survival for patients who undergo liver resection for CRLM approaches nearly 70% .2 Unfortunately, up to 80% of patients with CRLM are not candidates for surgical resection at initial presentation3,4 and up to 50%-60% of patients develop disease recurrence after a curative-intent hepatic resection.5  \nThe cornerstone of the management of unresectable CRLM remains systemic chemotherapy. The primary goals of systemic therapy are to reduce disease progression, improve quality of life, and potentially, downstage patients to resectability. Historically,ﬁve-year overall survival (OS) for these patients has approximated 10% . Even with advances in chemotherapy regimens, only 20%–40% of patients respond well enough to become  \ncandidates for liver resection.6 Alternative therapies have been proposed and studied. The addition of immune checkpoint blockade to chemotherapy for the small subset of patients with MSI-H/dMMR cancers (5%) has been shown to double median progression free survival (PFS) .7 The use of hepatic artery infusion pumps in conjunction with systemic chemotherapy may potentially improve resectability and survival at the expense of increased toxicity in nonrandomized trials. The upcoming EA222 PUMP trial (NCT05863195) seeks to explore this in a randomized setting. Locoregional therapies have also been studied. Radiofrequency ablation is a good option for patients with fewer, relatively small lesions that are not located near major  \n1 Department of Surgery, University of Pennsylvania, Philadelphia, PA, USA 2Department of Medicine,","cbCaiibmre2DRPqV","https://ap.wps.com/l/cbCaiibmre2DRPqV","pdf",403596,"English","# Abstract\n# Introduction\n## Systemic chemotherapy and goals\n## Alternative and locoregional therapies\n## Historical and renewed interest in liver transplantation","[{\"question\":\"Why are many patients with colorectal liver metastases (CRLM) not eligible for surgery initially?\",\"answer\":\"Up to about 80% of patients with CRLM are not candidates for surgical resection at initial presentation, and recurrence remains common after curative-intent hepatic resection.\"},{\"question\":\"What is the primary treatment approach for unresectable CRLM?\",\"answer\":\"Systemic chemotherapy is the cornerstone for unresectable CRLM, aiming to reduce progression, improve quality of life, and potentially downstage patients to resectability.\"},{\"question\":\"What factors led to renewed interest in liver transplantation for unresectable CRLM?\",\"answer\":\"Advances in surgical technique, better immunosuppression, expansion of the donor pool, and growing experience with liver transplant for hepatocellular carcinoma and hilar cholangiocarcinoma have renewed interest in this oncologic strategy.\"}]","Liver Transplantation for Unresectable Colorectal Liver Metastases | PDF",1790192583,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/621d974a40d60f1b5610493b53948563.webp",983,1276,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa165f3bac0b7cc1ede7dacfb0a51a9b.webp",982,1275,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a27c374e87fdacc1e0514d45a8034e28.webp",981,1273,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fed19ad1b6ca6ae2d7d3e85b97d681c6.webp",980,1272]